Shilpa Medicare Beheer

Beheer criteriumcontroles 4/4

De CEO Shilpa Medicare is Vishnukanth Bhutada, benoemd in Aug2022, heeft een ambtstermijn van 2.25 jaar. De totale jaarlijkse vergoeding van { bedraagt ₹ 35.00M, bestaande uit 100% salaris en 0% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 8.87% van de aandelen van het bedrijf, ter waarde ₹ 7.21B. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 2.5 jaar en 3.2 jaar.

Belangrijke informatie

Vishnukanth Bhutada

Algemeen directeur

₹35.0m

Totale compensatie

Percentage CEO-salaris	100.0%
Dienstverband CEO	2.3yrs
Eigendom CEO	8.9%
Management gemiddelde ambtstermijn	2.5yrs
Gemiddelde ambtstermijn bestuur	3.2yrs

Recente managementupdates

Recent updates

Analyse CEO-vergoeding

Hoe is Vishnukanth Bhutada's beloning veranderd ten opzichte van Shilpa Medicare's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Sep 30 2024	n/a	n/a	₹611m
Jun 30 2024	n/a	n/a	₹448m
Mar 31 2024	₹35m	₹35m	₹319m
Dec 31 2023	n/a	n/a	-₹7m
Sep 30 2023	n/a	n/a	-₹119m
Jun 30 2023	n/a	n/a	-₹321m
Mar 31 2023	₹35m	₹35m	-₹325m
Dec 31 2022	n/a	n/a	₹51m
Sep 30 2022	n/a	n/a	₹213m
Jun 30 2022	n/a	n/a	₹599m
Mar 31 2022	₹97m	₹16m	₹607m
Dec 31 2021	n/a	n/a	₹395m
Sep 30 2021	n/a	n/a	₹376m
Jun 30 2021	n/a	n/a	₹631m
Mar 31 2021	₹97m	₹16m	₹1b
Dec 31 2020	n/a	n/a	₹2b
Sep 30 2020	n/a	n/a	₹2b
Jun 30 2020	n/a	n/a	₹2b
Mar 31 2020	₹99m	₹10m	₹2b
Dec 31 2019	n/a	n/a	₹1b
Sep 30 2019	n/a	n/a	₹1b
Jun 30 2019	n/a	n/a	₹944m
Mar 31 2019	₹75m	₹10m	₹1b
Dec 31 2018	n/a	n/a	₹1b
Sep 30 2018	n/a	n/a	₹1b
Jun 30 2018	n/a	n/a	₹1b
Mar 31 2018	₹81m	₹16m	₹1b

Compensatie versus markt: De totale vergoeding ($USD 414.23K ) Vishnukanth } is ongeveer het gemiddelde voor bedrijven van vergelijkbare omvang in de Indian markt ($USD 356.09K ).

Compensatie versus inkomsten: De vergoeding van Vishnukanth is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.

CEO

Vishnukanth Bhutada (62 yo)

2.3yrs

Tenure

₹35,000,000

Compensatie

Mr. Vishnukanth Chaturbhuj Bhutada, B. Pharm. serves as the Managing Director of Shilpa Medicare Limited since August 11, 2022 . Mr. Bhutada joined Shilpa Medicare Limited in November 1987.He serves as th...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Vishnukanth Bhutada	MD & Director	2.3yrs	₹35.00m	8.87% ₹ 7.2b
Alpesh Dalal	Chief Financial Officer	3.5yrs	₹14.73m	0.0023% ₹ 1.9m
Sharath Kalakota	VP of Projects & Operations and Whole-Time Director	no data	₹16.26m	0.032% ₹ 26.3m
Ritu Tiwary	Company Secretary & Compliance Officer	2.5yrs	₹4.51m	geen gegevens
Jayant Karajgi	Chief Operating Officer of Formulations	no data	₹26.95m	geen gegevens
Ganeshchandra Sonavane	President of Global R&D	no data	₹11.50m	geen gegevens
Rajeev Saxena	Senior Vice President – Domestic Formulations and Biologics	no data	₹3.90m	geen gegevens
Abhay Sapre	Senior Vice President of Formulation	no data	₹12.50m	geen gegevens
Smita Holey	Executive Vice President – Formulations for Small Molecules	no data	₹2.50m	geen gegevens
Awez Pathan	Vice President	no data	₹12.77m	geen gegevens
Pramod Kumar	Senior Vice President of Technical	no data	₹6.06m	geen gegevens
P. V. Rao	Chief Human Resource Officer	no data	geen gegevens	geen gegevens

2.5yrs

Gemiddelde duur

53.5yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van 530549 wordt beschouwd als ervaren (gemiddelde ambtstermijn 2.5 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Vishnukanth Bhutada	MD & Director	37yrs	₹35.00m	8.87% ₹ 7.2b
Sharath Kalakota	VP of Projects & Operations and Whole-Time Director	5.1yrs	₹16.26m	0.032% ₹ 26.3m
Arvind Vasudeva	Non-Executive Independent Director	3.2yrs	₹3.00m	geen gegevens
Kamal Sharma	Non-Executive Independent Director	2.3yrs	₹3.00m	geen gegevens
Hetal Gandhi	Non-Executive Independent Director	3.2yrs	₹4.00m	0.0092% ₹ 7.5m
Om Inani	Non-Executive Chairman	36.7yrs	₹350.00k	3.3% ₹ 2.7b
Anita Bandyopadhyay	Independent Women Director	2.3yrs	₹1.80m	geen gegevens

3.2yrs

Gemiddelde duur

62yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van 530549 wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.2 jaar).

Shilpa Medicare Beheer

Beheer criteriumcontroles 4/4

Belangrijke informatie

Recente managementupdates

Shilpa Medicare Limited, Annual General Meeting, Sep 17, 2024

Shilpa Medicare Limited, Annual General Meeting, Sep 17, 2024

Shilpa Medicare Limited, Annual General Meeting, Sep 29, 2023

Shilpa Medicare Limited Announces Change in Directorate

High number of new directors

Shilpa Medicare Limited Announces Board Changes

Recent updates

Second quarter 2025 earnings released: EPS: ₹1.83 (vs ₹0.19 in 2Q 2024)

Shilpa Medicare Limited to Report Q2, 2025 Results on Nov 13, 2024

Shilpa Medicare Limited's CDMO Customer Receives Fast-Track Designation for Its Investigational Drug Candidate

Shilpa Medicare Limited Completes Phase 1 Trial for Recombinant Human Albumin (rHA) 20%

Shilpa Medicare Limited Announces the Approval of Its Second Nda, Injection, by Usfda

Shilpa Medicare Limited, Annual General Meeting, Sep 17, 2024

First quarter 2025 earnings released: EPS: ₹1.46 (vs ₹0.14 in 1Q 2024)

Shilpa Medicare Limited, Annual General Meeting, Sep 17, 2024

Shilpa Medicare Limited to Report Q1, 2025 Results on Aug 08, 2024

Full year 2024 earnings released: EPS: ₹3.67 (vs ₹3.74 loss in FY 2023)

Shilpa Medicare Limited to Report Q4, 2024 Results on May 23, 2024

Shilpa Medicare Limited has filed a Follow-on Equity Offering in the amount of INR 5 billion.

Shilpa Medicare Limited has filed a Follow-on Equity Offering in the amount of INR 5 billion.

Shilpa Medicare Limited has filed a Follow-on Equity Offering in the amount of INR 5 billion.

Third quarter 2024 earnings released: EPS: ₹0.53 (vs ₹0.76 loss in 3Q 2023)

Shilpa Medicare Limited to Report Q3, 2024 Results on Feb 08, 2024

Shilpa Medicare Limited and Celltrion, Inc. Announce Arbitration

Shilpa Medicare Limited and Celltrion, Inc. Announce Arbitration

Second quarter 2024 earnings released: EPS: ₹0.19 (vs ₹2.15 loss in 2Q 2023)

Shilpa Medicare Limited to Report Q2, 2024 Results on Nov 10, 2023

Shilpa Medicare Limited Launches Naturally Derived Option for the Treatment of Oral Mucositis in India Under the Brand Name Oraal

Shilpa Medicare Limited, Annual General Meeting, Sep 29, 2023

First quarter 2024 earnings released: EPS: ₹0.14 (vs ₹0.10 in 1Q 2023)

Shilpa Medicare Limited to Report Q1, 2024 Results on Aug 10, 2023

New minor risk - Share price stability

Full year 2023 earnings released: ₹3.74 loss per share (vs ₹7.26 profit in FY 2022)

Shilpa Medicare Limited Announces New Drug Application for Pemetrexed Injection 1000 mg/100 ml, 500 mg/50 mg/50 mg & 100 mg/10 mg/10 mgl, Ready to Use Form Form Formulation Is Approved By US FDA

Shilpa Medicare Limited Announces US FDA GMP Inspection Cleared with VAI Classification

Shilpa Medicare Limited to Report Q4, 2023 Results on May 25, 2023

Shilpa Medicare Limited, Unit Vi, Bengaluru Facility Has Successfully Registered with Ministry of Health, United Arab Emirates

Third quarter 2023 earnings released

Shilpa Medicare Limited to Report Q3, 2023 Results on Feb 14, 2023

Shilpa Medicare Limited announces Launch of its New Brand Capebel (Capecitabine 1000 Mg Dispersible Tablet)

Shilpa Medicare Limited's Unit IV Facility Receives Health Canada GMP Approval

Second quarter 2023 earnings released: ₹2.15 loss per share (vs ₹2.45 profit in 2Q 2022)

Shilpa Medicare Reportedly Plans API Biz Stake Sale

Shilpa Medicare Limited to Report Q2, 2023 Results on Nov 11, 2022

Shilpa Medicare Approves Dividend for the Financial Year Ended 31 March 2022

Shilpa Medicare Limited Announces Change in Directorate

Shilpa Medicare Limited, Analytical Services Division, Nacharam, Hyderabad, Telangana Receives US FDA Clearance for the Facility

Shilpa Medicare Limited Announces Its Successful Innovation of First in World Topical Hemostatic Spray of Tranexamic Acid Has Received CDSCO Approval

Shilpa Medicare Limited Receives U.S Food and Drug Administration Tentative Approval for Its Anda, Tenofovir Alafenamide Tablets

Upcoming dividend of ₹1.10 per share

High number of new directors

Shilpa Medicare Limited Announces Board Changes

First quarter 2023 earnings released: EPS: ₹0.10 (vs ₹0.19 in 1Q 2022)

Shilpa Medicare Limited, Annual General Meeting, Sep 28, 2022

Shilpa Medicare Limited Appoints Kamal K Sharma as an Additional Independent Director

Price target decreased to ₹355

Consensus forecasts updated

Shilpa Medicare Limited Appoints Ritu Tiwary as Company Secretary & Compliance Officer

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Shilpa Medicare Limited to Report Fiscal Year 2022 Final Results on May 23, 2022

Shilpa Medicare Limited Via Shilpa Biologicals Private Limited Receive NoC from RCGM, Dept of Biotechnology to Approach the DCGI to Conduct Clinical Studies for its Biosimilar Aflibercept

Consensus forecasts updated

Shilpa Medicare Limited Announces Board Resignations

Third quarter 2022 earnings: EPS in line with analyst expectations despite revenue beat

Shilpa Medicare Limited to Report Q3, 2022 Results on Feb 08, 2022

High number of new directors

Second quarter 2022 earnings released: EPS ₹2.45 (vs ₹5.57 in 2Q 2021)

High number of new directors

Upcoming dividend of ₹1.10 per share

First quarter 2022 earnings released: EPS ₹0.19 (vs ₹10.59 in 1Q 2021)

Price target increased to ₹511

Investor sentiment improved over the past week

Shilpa Medicare Limited Receives In-Principle Approval From Defence Research & Development Organisation (DRDO) For Technology Transfer, Manufacture And Supply Of 2-Deoxy-D-Glucose (2DG)

Consensus forecasts updated

Shilpa Medicare Limited Recommends Dividend for the Financial Year 2020-2021

Full year 2021 earnings released: EPS ₹18.13 (vs ₹19.15 in FY 2020)